日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer

循环肿瘤DNA在早期乳腺癌新辅助内分泌治疗中的应用

Grinshpun, A; Dustin, D; Cai, M; Hughes, M; DiLullo, M; Moore, M; Yardley, D; Mayer, I A; Symmans, W F; Mayer, E L; Winer, E P; Lin, N U; Tolaney, S M; Metzger, O; Jeselsohn, R

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

HER2低表达转移性三阴性乳腺癌的雄激素受体表达和免疫特征

Tarantino, Paolo; Cha, Jaeyoon; Binboga Kurt, Busem; Chu, Xiangying; Jovanović, Bojana; Zhou, Andrew; Hughes, Melissa; Russo, Douglas; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Lin, Nancy U; Carter, Jamie; Chen, Yisang Serenity; Li, Tianyu; Tayob, Nabihah; Mittendorf, Elizabeth A; Schnitt, Stuart J; Goel, Shom; Tolaney, Sara M

The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)

新诊断的浸润性乳腺癌和导管原位癌(DCIS)患者肠道微生物组概况

Sammons, Sarah L; Kuntz, Thomas M; DiLullo, Molly; Morgan, Xochitl C; Martin, Alyssa; Hughes, Melissa E; Rahman, Tasnim; Barroso-Sousa, Romualdo; Ogayo, Esther Ritah; Giordano, Julia; Ryan, Sean; Waks, Adrienne G; Schlam, Ilana; Ligibel, Jennifer; Lin, Nancy U; Garrido-Castro, Ana C; Mittendorf, Elizabeth A; Tolaney, Sara M

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

新辅助紫杉醇联合帕博利珠单抗治疗激素受体阳性乳腺癌的疗效、安全性及预测性生物标志物:一项随机试点试验

Waks, Adrienne G; Fu, Jingxin; Chu, Xiangying; Binboga Kurt, Busem; Li, Tianyu; Kuntz, Thomas M; Shen, Yizhuo; Yang, David; Meli, Kevin; Reardon, Brendan; Park, Jihye; Partridge, Ann; Abravanel, Daniel; Jeselsohn, Rinath; Wrabel, Eileen; Alberti, Jillian; DiLullo, Molly; Chen, Serenity; Mohammed-Abreu, Ayesha; Sun, Xiaopeng; Balko, Justin M; Kleijn, Miranda; Audeh, William; Morgan, Xochitl C; Krop, Ian E; Tayob, Nabihah; Van Allen, Eliezer M; Mittendorf, Elizabeth A; Tolaney, Sara M

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

早期原发性激素受体阳性乳腺癌抗PD-1和化疗期间的细胞重编程

Fu, Jingxin; Waks, Adrienne G; Pimenta, Erica; Titchen, Breanna; Bi, Kevin; Camp, Sabrina; Pappa, Theodora; Keenan, Tanya; Shannon, Erin; Vigneau, Sébastien; Bemus, Meredith; Nag, Anwesha; Thorner, Aaron R; Park, Jihye; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Mittendorf, Elizabeth A; Abravanel, Daniel L; Tolaney, Sara M; Van Allen, Eliezer M

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

纳武利尤单抗联合低剂量伊匹木单抗治疗高突变 HER2 阴性转移性乳腺癌:一项 II 期试验 (NIMBUS)

Barroso-Sousa, Romualdo; Zanudo, Jorge Gomez Tejeda; Li, Tianyu; Reddy, Sangeetha M; Emens, Leisha A; Kuntz, Thomas M; Silva, Carolina Alves Costa; AlDubayan, Saud H; Chu, Hoyin; Overmoyer, Beth; Lange, Paulina; DiLullo, Molly K; Montesion, Meagan; Kasparian, Julie; Hughes, Melissa E; Attaya, Victoria; Basta, Ameer; Lin, Nancy U; Tayob, Nabihah; Jeselsohn, Rinath; Mittendorf, Elizabeth A; Tolaney, Sara M

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

一项针对转移性激素受体阳性乳腺癌或晚期卵巢癌患者的I期研究,评估了ribociclib(CDK4/6抑制剂)联合spartalizumab(PD-1抑制剂)以及单独使用或不联合fulvestrant的疗效。

Ana C Garrido-Castro ,Noah Graham ,Lestat R Ali ,Christina Herold ,Jennifer Desrosiers ,Khanh Do ,Heather Parsons ,Tianyu Li ,Shom Goel ,Molly DiLullo ,Eileen Wrabel ,Amy J Williams ,Joyce F Liu ,Elizabeth A Mittendorf ,Stephanie K Dougan ,Nabihah Tayob ,Geoffrey I Shapiro ,Sara M Tolaney

A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

一项针对视网膜母细胞瘤阳性、转移性三阴性乳腺癌患者的阿贝西利II期研究

Goel, Shom; Jovanović, Bojana; Chu, Xiangying; Hughes, Melissa; Erick, Timothy K; Russo, Douglas; DiLullo, Molly; Wrabel, Eileen; Jeselsohn, Rinath; Lin, Nancy U; Tayob, Nabihah; Mittendorf, Elizabeth; Schnitt, Stuart; Tolaney, Sara M

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers

HER2阳性炎性乳腺癌中的HER2DX:相关性分析及与非炎性乳腺癌的比较分析

Lynce, F; Martínez-Sáez, O; Walbaum, B; Brasó-Maristany, F; Waks, A G; Villagrasa, P; Villacampa Javierre, G; Sanfeliu, E; Galván, P; Paré, L; Anderson, L M; Perou, C M; Parker, J S; Vivancos, A; DiLullo, M K; Pernas, S; Winer, E P; Overmoyer, B; Mittendorf, E A; Bueno-Muiño, C; Martín, M; Prat, A; Tolaney, S M

Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients

免疫疗法治疗的早期HR+乳腺癌患者的动态单细胞系统性免疫反应

Xiaopeng Sun ,Margaret L Axelrod ,Adrienne G Waks ,Jingxin Fu ,Molly DiLullo ,Eliezer M Van Allen ,Sara M Tolaney ,Elizabeth A Mittendorf ,Yaomin Xu ,Justin M Balko